Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Last $14.57 USD
Change Today -0.10 / -0.68%
Volume 627.6K
MNTA On Other Exchanges
As of 5:20 PM 03/6/15 All times are local (Market data is delayed by at least 15 minutes).
text size: T | T
Back to Snapshot
Company Description

Contact Info

675 West Kendall Street

Cambridge, MA 02142

United States

Phone: 617-491-9700

Fax: 617-621-0431

Momenta Pharmaceuticals, Inc., a biotechnology company, is engaged in the structural characterization, process engineering, and biologic systems analysis of complex molecules in the areas of complex generics, biosimilars, and novel drugs. Product Areas Complex Generics Enoxaparin Sodium Injection—Generic Lovenox Enoxaparin Sodium Injection, the company’s primay product to receive marketing approval under an Abbreviated New Drug Application (ANDA), is a generic version of Lovenox. Lovenox is a complex drug consisting of a mixture of polysaccharide chains and is a low molecular weight heparin (LMWH), used for the prevention and treatment of deep vein thrombosis, or DVT, and to support the treatment of acute coronary syndromes (ACS). Lovenox is distributed worldwide by Sanofi-Aventis U.S. LLC (Sanofi) and is also known outside the United States as Clexane and Klexane. The company has a collaboration and license agreement, or the 2003 Sandoz Collaboration, with Sandoz N.V. and Sandoz Inc. to jointly develop, manufacture and commercialize Enoxaparin Sodium Injection in the United States. M356—Generic Copaxone (glatiramer acetate injection) The company’s second complex generic product candidate, M356, is designed to be a generic version of Copaxone (glatiramer acetate injection), a complex drug consisting of a synthetic mixture of polypeptide chains. Copaxone is indicated for treatment of patients with relapsing-remitting multiple sclerosis, a chronic disease of the central nervous system characterized by inflammation and neurodegeneration. Under the Second Sandoz Collaboration Agreement, the company and Sandoz AG agreed to exclusively collaborate on the development and commercialization of M356, among other products. In North America, Copaxone is marketed by Teva Neuroscience, Inc., which is a subsidiary of Teva Pharmaceutical Industries Ltd. (Teva). Biosimilars The company is applying its complex systems analysis platform to the development of biosimilar versions of marketed therapeutic proteins. In 2011, the company and Baxter International, Inc., Baxter Healthcare Corporation and Baxter Healthcare SA, collectively, Baxter, entered into a global collaboration and license agreement, or the Baxter Agreement, to develop and commercialize biosimilars. Under the Baxter Agreement, the company and Baxter agreed to collaborate, on a world-wide basis, on the development and commercialization of two biosimilars, M923 and M834. M923, a biosimilar for a branded biologic indicated for certain autoimmune and inflammatory diseases, is its most advanced biosimilar. The company is working toward progressing this program to the clinic in Europe, which is targeted for the second half of 2014. M834, a biosimilar for a branded biologic indicated for certain autoimmune and inflammatory diseases. The company is working toward achievement of a pre-defined minimum development criteria license payment in 2014. Novel Drugs The company’s drugs program uses the established characterization and process engineering capabilities from its complex generics and biosimilars programs—with a focus on polysaccharides and therapeutic proteins. M402 M402 is an oncology drug candidate engineered to have a range of effects on tumor cells. In 2012, the company initiated a Phase 1/2 proof-of-concept clinical study in patients with advanced metastatic pancreatic cancer. The trial consists of two parts and would evaluate the safety, potential efficacy, pharmacokinetics and pharmacodynamics of M402 in combination with nab-paclitaxel and gemcitabine. Research and Development Expenses For the year ended December 31, 2013, the company’s research and development expense included $104.0 million. Significant Events The company has an agreement with the Massachusetts Institute of Technology, or M.I.T., granting it various exclusive and non-exclusive worldwide licenses, with the right to grant sublicenses, under certain patents and patent applications relating to methods and technologies for characterizing polysaccharides; certain heparins, heparinases and other enzymes; and carbohydrate synthesis methods. Patents

Page 12Next Page

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
MNTA:US $14.57 USD -0.10

MNTA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Natco Pharma Ltd 1,509 INR +14.35
OraSure Technologies Inc $7.17 USD +0.06
Pernix Therapeutics Holdings Inc $11.78 USD +0.28
SciClone Pharmaceuticals Inc $8.00 USD -0.09
Sucampo Pharmaceuticals Inc $15.64 USD +0.49
View Industry Companies

Industry Analysis


Industry Average

Valuation MNTA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 14.7x
Price/Book 3.8x
Price/Cash Flow NM Not Meaningful
TEV/Sales 11.8x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact MOMENTA PHARMACEUTICALS INC, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at